Urologia Internationalis · 2005 · 27 citations · 18 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaTumor PathologyBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyBladder CancerCancer ProgressionTumor CharacterizationTumor MarkersBladder Cancer DiagnosisBladder PathologyBladder Tumor CharacterizationMedical Records ReviewPten InactivationPten SignalingTumor Stage PrognosisWestern Blotting
INTRODUCTION: The prognostic significance of PTEN protein loss in bladder cancer is not well established. The objective of this study was to investigate the PTEN expression profile in superficial noninvasive papillary transitional cell carcinoma (TCC) versus invasive TCC and compared the results with pathological and clinical parameters. MATERIALS AND METHODS: Bladder tumor samples were obtained from 29 patients who underwent surgery for superficial (n=11) and invasive (n=18) bladder cancers at the Akdeniz University Hospital. The patient profile including sex, age, histological grade and the stage, presence of carcinoma in situ, cystoscopy findings (tumor size, location, multiplicity) were obtained by examining the patients' medical records. No patient received anticancer agents prior to the operation. Western blotting was performed using bladder carcinoma samples in order to determine the level of PTEN protein expression for each patient. RESULTS: Only 4 (13.7%) patients with bladder carcinoma manifested a decrease in the level of PTEN expression. Regarding the correlation between tumor stage and the PTEN expression, with the exception of patient 23 all patients who displayed a reduction in PTEN expression had muscle-invasive TCC. CONCLUSION: Future studies with a clinical follow-up will be needed to determine if those superficial tumors with decreased PTEN expression are going to progress to a later stage. Based on our results PTEN by itself does not seem to be a good candidate as an independent marker to predict the behavior of bladder cancers.
18
Jing Li, Clifford Yen, Danny Liaw et al. · Science · 1997 · 4.8K citations
Sarah Landis, Thomas S. Murray, S. Bolden et al. · CA A Cancer Journal for Clinicians · 1999 · 3.1K citations · Full text
Medicine, Biostatistics, Oncology +17
Salih Şanlıoğlu, Carl M. Williams, Lobelia Samavati et al. · Journal of Biological Chemistry · 2001 · 392 citations · Full text
Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers
Paul Cairns, Ella Evron, Kenji Okami et al. · Oncogene · 1998 · 180 citations
Somatic mutation of PTEN in bladder carcinoma
J S Aveyard, Amy Skilleter, Tomonori Habuchi et al. · British Journal of Cancer · 1999 · 138 citations · Full text